Novo Nordisk CEO: We are a cardiometabolic powerhouse

132721 ProInvestorNEWS 10/6 2026 22:11

At the American Diabetes Association's 2026 Scientific Sessions, CNBC's Angelica Peebles sat down with Novo Nordisk CEO Mike Doustdar to discuss what to expect from Novo's pipeline and strategy in the years to come. "We're going to be very diversified," he says. "But all of it within the area of cardiometabolics, per se. Diabetes, obesity, cardiometabolic, and some of the adjacencies."

10/6 2026 22:55 Occam 2

132723

Det er en fornøjelse at høre ham tale. Godt at han arbejder for os.

10/6 2026 23:55 bb8 1

132724

AstraZeneca obesity pill helps patients lose 10.5% of body weight in trial
https://www.reuters.com/legal/litigation/astrazeneca-obesity-pill-helps-patients-lose-105-body-weight-trial-2026-06-08/

===

Meget af nedenstaaende er bag betalingsvaeg. Den foerste af de to Lancet-artikler er pudsigt nok ikke bag betalings-vaeg, saa jeg har tilladt mig at poste figur 2a-d derfra. Figurerne med sort baggrund er ikke fra Lancet. Bemaerk det ikke er data fra head-to-head trials. Klik for at goere figurerne stoerre.

===

Først skulle Novo fokusere - nu vil Doustdar udvide igen
https://finans.dk/erhverv/ECE19367476/foerst-skulle-novo-fokusere-nu-vil-doustdar-udvide-igen/

Vigtig sejr for Doustdar: Novo banker rival i pillekrig
https://finans.dk/erhverv/ECE19372751/vigtig-sejr-for-doustdar-novo-banker-rival-i-pillekrig/

===

Elecoglipron, an oral small molecule GLP-1 RA, moves to Phase III programme and unlocks next chapter in AstraZeneca's cardiometabolic and kidney portfolio
https://www.astrazeneca.com/media-centre/press-releases/2026/elecoglipron-an-oral-small-molecule-glp-1-ra-moves-to-phase-iii-programme.html

Elecoglipron, an oral small molecule GLP-1 receptor agonist in adults with obesity or overweight (VISTA): a multicentre, phase 2, randomised, placebo-controlled clinical trial
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)00748-8/fulltext

Elecoglipron, an oral small molecule GLP-1 receptor agonist in adults with type 2 diabetes (SOLSTICE): a multicentre, phase 2b, randomised, placebo-controlled trial
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)00802-0/abstract

11/6 2026 00:11 bb8 0

132725

0:57 "All of these are peptides. I think it is really important. The pills that we are working on, they are not small molecules, they are POWERFUL PEPTIDES IN A PILL."

Caps lock satte sig fast ;−)

Deres trippel-agonist UBT251 lyder vild. 19,7% vaegt-tab efter 24 uger med "excellent tolerability". Wow! Lilly skal staa tidligt op i 2028.

TRÅDOVERSIGT

132721 Novo Nordisk CEO: We are a cardiometabolic powerhouse
10/6 22:11 ProInvestorNEWS 7

132723 Det er en fornøjelse at høre ham tale. Go..
10/6 22:55 Occam 2

132724 AstraZeneca obesity pill helps patients l..
10/6 23:55 bb8 1

132725 0:57 "All of these are peptides. I t..
11/6 00:11 bb8 0